Of particular note, GBM exhibited significant upregulation of NUCB2, alongside other malignancies such as breast carcinoma (BRCA), oesophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), kidney chromophobe carcinoma (KICH), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), colorectal adenocarcinoma (READ), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD) and thyroid carcinoma (THCA). This evidence concerns the gene NUCB2 and breast carcinoma.